SS1
MCID: SRC025
MIFTS: 72

Sarcoidosis 1 (SS1)

Categories: Bone diseases, Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Sarcoidosis 1

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 57 74 6
Sarcoidosis 57 12 75 53 59 74 55 43 44 15 63 72 33
Boeck Sarcoid 57 12 59 74
Sarcoidosis, Susceptibility to, 1 57 13
Besnier-Boeck-Schaumann Disease 59 74
Ss1 57 74
Sarcoidosis, Susceptibility to, Type 1 40
Lymphogranulomatosis 12
Schaumann's Disease 53
Sarcoid of Boeck 53
Hodgkin Disease 72
Boeck's Sarcoid 59

Characteristics:

Orphanet epidemiological data:

59
sarcoidosis
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide),1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Miscellaneous:
generalized fatigue
onset usually before age 40 years
systemic granulomatous disease
u.s. frequency higher in blacks than whites

Inheritance:
autosomal dominant


HPO:

32
sarcoidosis 1:
Inheritance autosomal dominant inheritance sporadic


Classifications:



External Ids:

Disease Ontology 12 DOID:11335
OMIM 57 181000
ICD9CM 35 135
MeSH 44 D012507
NCIt 50 C34995
SNOMED-CT 68 31541009
MESH via Orphanet 45 D012507
ICD10 via Orphanet 34 D86.0 D86.1 D86.2 more
UMLS via Orphanet 73 C0036202
Orphanet 59 ORPHA797
UMLS 72 C0019829 C0036202

Summaries for Sarcoidosis 1

NIH Rare Diseases : 53 Sarcoidosis is an inflammatory disease characterized by the development and growth of tiny lumps of cells called granulomas. If these tiny granulomas grow and clump together in an organ, they can affect the organ's structure and function. Overtime, this can lead to permanent scarring or thickening of the organ tissue (also called fibrosis). Although the granulomas can be found in almost any part of the body, they occur most commonly in the lungs and lymph nodes. Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The exact cause of sarcoidosis is poorly understood. In many cases, treatment is not necessary and sarcoidosis will resolve on its own. However, therapies such as corticosteroids, immunosuppressants, and antimalarial drugs, are available to control symptoms, prevent complications, and improve outcomes.

MalaCards based summary : Sarcoidosis 1, also known as sarcoidosis, is related to skin sarcoidosis and blau syndrome, and has symptoms including snoring and coughing. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Riociguat have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotypes are fever and fatigue

Disease Ontology : 12 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

MedlinePlus : 43 Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body. No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include Cough Shortness of breath Weight loss Night sweats Fatigue Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute

UniProtKB/Swiss-Prot : 74 Sarcoidosis 1: An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

PubMed Health : 63 About sarcoidosis: Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances. For example, it sends special cells to protect organs that are in danger. These cells release chemicals that recruit other cells to isolate and destroy the harmful substance. Inflammation occurs during this process. Once the harmful substance is gone, the cells and the inflammation go away. In people who have sarcoidosis, the inflammation doesn't go away. Instead, some of the immune system cells cluster to form lumps called granulomas (gran-yu-LO-mas) in various organs in your body.

Wikipedia : 75 Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as... more...

More information from OMIM: 181000

Related Diseases for Sarcoidosis 1

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2 Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1486)
# Related Disease Score Top Affiliating Genes
1 skin sarcoidosis 35.1 TNFRSF1B TNF ACE
2 blau syndrome 34.7 TNF NOD2 IL1B
3 beryllium disease 33.7 TNF HLA-DRB1
4 uveoparotid fever 33.6 TNF ACE
5 melkersson-rosenthal syndrome 33.5 TNFRSF1B TNF NOD2 ACE
6 intermediate uveitis 33.2 TNF IL2RA IFNG CXCR3
7 interstitial lung disease 33.2 TNF IL1B IFNG CCL2
8 orofacial granulomatosis 32.9 TNF NOD2 IFNG CXCR3 CCL3 BTNL2
9 idiopathic interstitial pneumonia 31.9 IFNG ICAM1 CCL2
10 leprosy 3 31.7 TNF NOD2 IFNG
11 lung disease 31.7 TNF IL1B CXCR3 CCL3 CCL2
12 panuveitis 31.6 TNFRSF1B TNF HLA-DRB1
13 vasculitis 31.6 TNFRSF1B TNF ICAM1 CCL2
14 posterior uveitis 31.6 TNF IL2RA IFNG
15 autoimmune disease 31.6 TNF IL2RA IL1B IFNG HLA-DRB1
16 chronic beryllium disease 31.6 TNF IFNG HLA-DRB1
17 uveitis 31.5 TNF NOD2 IL2RA IFNG ICAM1 CXCR3
18 myocarditis 31.4 TNF IL12RB1 ICAM1
19 extrinsic allergic alveolitis 31.4 IL2RA IL1B IL18 CXCR3 CCL2
20 spondyloarthropathy 1 31.3 TNFRSF1B TNF NOD2
21 bronchiolitis 31.3 TNF IFNG CCL3
22 glomerulonephritis 31.3 MIF IL1B ICAM1 CCL2
23 connective tissue disease 31.3 TNF IFNG HLA-DRB1 ACE
24 pulmonary tuberculosis 31.2 TNF IL18 IL12RB1 IFNG HLA-DRB1 CCL3
25 miliary tuberculosis 31.2 TNF IL12RB1 IFNG
26 pericarditis 31.2 TNF IL1B IFNG
27 pneumoconiosis 31.2 TNF IL1B CCL2
28 crohn's colitis 31.2 TNF NOD2 IL1B IFNG
29 spondylitis 31.2 TNFRSF1B TNF NOD2 LTA
30 optic neuritis 31.2 TNF LTA HLA-DRB1
31 ulcerative colitis 31.2 TNF NOD2 IL1B IFNG BTNL2
32 mycobacterium tuberculosis 1 31.2 TNFRSF1B TNF IL18 IL12RB1 IFNG CXCR3
33 pleurisy 31.2 TNF IFNG ICAM1 CCL2
34 neuritis 31.1 TNF IL1B IFNG CCL2
35 keratoconjunctivitis 31.1 TNF IFNG ICAM1
36 inflammatory bowel disease 31.1 TNF NOD2 IL1B IL18 IFNG
37 colitis 31.1 TNF NOD2 IL1B IFNG BTNL2
38 pneumonia 31.1 TNF IL1B CCL3 CCL2
39 granulomatous dermatitis 31.0 TNFRSF1B TNF NOD2 ACE
40 bronchiolitis obliterans 31.0 TNF SCGB1A1 IFNG CXCR3
41 aseptic meningitis 31.0 TNF IL1B IFNG
42 osteomyelitis 31.0 TNF IL1B IFNG
43 iga glomerulonephritis 31.0 SCGB1A1 CCL2 ACE
44 proliferative glomerulonephritis 31.0 IFNG CXCR3 CCL2
45 graves' disease 31.0 IL2RA IFNG ICAM1 HLA-DRB1
46 acute respiratory distress syndrome 31.0 TNF LTA IL1B
47 meningitis 30.9 TNF IL1B IFNG CCL3 CCL2
48 sleep apnea 30.9 TNF IL1B ICAM1 ACE
49 hashimoto thyroiditis 30.9 IL2RA IFNG ICAM1 CXCR3
50 mumps 30.9 TNF IL2RA IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Sarcoidosis 1:



Diseases related to Sarcoidosis 1

Symptoms & Phenotypes for Sarcoidosis 1

Human phenotypes related to Sarcoidosis 1:

59 32 (show top 50) (show all 93)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
2 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
3 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
4 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
5 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
6 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
7 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
8 thrombocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001873
9 uveitis 59 32 frequent (33%) Frequent (79-30%) HP:0000554
10 leukopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001882
11 erythema nodosum 59 32 frequent (33%) Frequent (79-30%) HP:0012219
12 increased t cell count 32 frequent (33%) HP:0100828
13 facial palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0010628
14 cataract 59 32 occasional (7.5%) Occasional (29-5%) HP:0000518
15 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
16 blindness 59 32 occasional (7.5%) Occasional (29-5%) HP:0000618
17 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
18 portal hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0001409
19 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
20 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
21 emphysema 59 32 occasional (7.5%) Occasional (29-5%) HP:0002097
22 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
23 heart block 59 32 occasional (7.5%) Occasional (29-5%) HP:0012722
24 alopecia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001596
25 hypercalciuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0002150
26 keratoconjunctivitis sicca 59 32 occasional (7.5%) Occasional (29-5%) HP:0001097
27 diabetes insipidus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000873
28 glaucoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0000501
29 hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001399
30 nephrocalcinosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000121
31 nephrolithiasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000787
32 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
33 proximal muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003701
34 abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0011024
35 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
36 bone cyst 59 32 occasional (7.5%) Occasional (29-5%) HP:0012062
37 bronchiectasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002110
38 hyperpigmentation of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0000953
39 pneumothorax 59 32 occasional (7.5%) Occasional (29-5%) HP:0002107
40 upper airway obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0002781
41 increased csf protein 59 32 occasional (7.5%) Occasional (29-5%) HP:0002922
42 ventricular tachycardia 59 32 occasional (7.5%) Occasional (29-5%) HP:0004756
43 chylothorax 59 32 occasional (7.5%) Occasional (29-5%) HP:0010310
44 tubulointerstitial nephritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001970
45 abnormality of the nasal mucosa 59 32 occasional (7.5%) Occasional (29-5%) HP:0000433
46 dacryocystitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000620
47 hypopigmentation of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0001010
48 enlarged lacrimal glands 59 32 occasional (7.5%) Occasional (29-5%) HP:0007734
49 enlargement of parotid gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0011801
50 parotitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011850

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
photophobia
glaucoma
uveitis
blurred vision
enlarged lacrimal glands
more
Respiratory:
dyspnea
cough

Abdomen Gastrointestinal:
anorexia
associated inflammatory bowel disease

Immunology:
generalized lymphadenopathy
hyperglobulinemia
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes

Head And Neck Mouth:
enlarged salivary glands

Abdomen Liver:
hepatomegaly may occur
elevated liver function tests may occur

Neurologic Central Nervous System:
neurosarcoidosis (5-16% of patients)

Metabolic Features:
fever

Growth Weight:
weight loss

Laboratory Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Skeletal:
polyarthritis
bone cysts

Respiratory Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Abdomen Spleen:
splenomegaly may occur

Hematology:
bone marrow involvement may cause pancytopenia

Clinical features from OMIM:

181000

UMLS symptoms related to Sarcoidosis 1:


snoring, coughing

GenomeRNAi Phenotypes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 ACE ICAM1 IL18 IL1B IL2RA LTA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 ACE ICAM1 IL18 IL1B IL2RA LTA

MGI Mouse Phenotypes related to Sarcoidosis 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.15 ACE ICAM1 IFNG IL12RB1 IL18 IL1B
2 hematopoietic system MP:0005397 10.13 ACE CXCR3 ICAM1 IFNG IL12RB1 IL18
3 homeostasis/metabolism MP:0005376 10.1 ACE CXCR3 ICAM1 IFNG IL12RB1 IL18
4 immune system MP:0005387 10.06 ACE CCL2 CHIT1 CXCR3 ICAM1 IFNG
5 neoplasm MP:0002006 9.61 ACE CXCR3 ICAM1 IFNG IL1B MIF
6 respiratory system MP:0005388 9.17 CXCR3 IFNG IL2RA LTA SCGB1A1 TNF

Drugs & Therapeutics for Sarcoidosis 1

PubMed Health treatment related to Sarcoidosis 1: 63

Not everyone who has sarcoidosis needs treatment. Sometimes the disease goes away on its own. Whether you need treatment and what type of treatment you need depend on your signs and symptoms, which organs are affected, and whether those organs are working well. If the disease affects certain organs—such as your eyes, heart, or brain—you'll need treatment even if you don't have any symptoms. In either case, whether you have symptoms or not, you should see your doctor for ongoing care. He or she will want to check to make sure that the disease isn't damaging your organs. For example, you may need routine lung function tests to make sure that your lungs are working well. If the disease isn't worsening, your doctor may watch you closely to see whether the disease goes away on its own. If the disease does start to get worse, your doctor can prescribe treatment. The goals of treatment include: Relieving symptomsImproving organ functionControlling inflammation and reducing the size of granulomas (inflamed lumps)Preventing pulmonary fibrosis (lung scarring) if your lungs are affected Your doctor may prescribe topical treatments and/or medicines to treat the disease.

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 534)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Riociguat Approved Phase 4 625115-55-1
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Epirubicin Approved Phase 4 56420-45-2 41867
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
leucovorin Approved Phase 4 58-05-9 143 6006
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
26 Narcotics Phase 4
27 Adrenergic alpha-2 Receptor Agonists Phase 4
28 Adrenergic Agonists Phase 4
29 Epinephryl borate Phase 4
30 Adrenergic alpha-Agonists Phase 4
31 Adrenergic Agents Phase 4
32 Analgesics, Opioid Phase 4
33 Dexmethylphenidate Hydrochloride Phase 4
34 Neurotransmitter Uptake Inhibitors Phase 4
35 Dopamine Uptake Inhibitors Phase 4
36 Dopamine Agents Phase 4
37 Hypnotics and Sedatives Phase 4
38 Anesthetics, General Phase 4
39 Anesthetics, Intravenous Phase 4
40 Adrenocorticotropic Hormone Phase 4
41 beta-endorphin Phase 4
42 Melanocyte-Stimulating Hormones Phase 4
43 Anticoagulants Phase 4
44 Micronutrients Phase 4
45 Trace Elements Phase 4
46 Citrate Phase 4
47 Ergocalciferols Phase 4
48 Nutrients Phase 4
49 Vitamin D2 Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1135)
# Name Status NCT ID Phase Drugs
1 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
2 ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
3 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
4 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
6 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
8 Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. Completed NCT00361387 Phase 4 d-methylphenidate
9 Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel Completed NCT02298491 Phase 4 H.P. Acthar Gel
10 Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. Completed NCT02246023 Phase 4
11 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
12 ACTHAR Therapy for Central Nervous System Sarcoidosis Recruiting NCT02920710 Phase 4 Repository Corticotropin Injection
13 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Recruiting NCT03549598 Phase 4 68Ga-DOTATATE PET/CT;18FDG PET/CT scan;13NH3 PET/CT scan
14 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis Recruiting NCT03320070 Phase 4 repository corticotropin injection;Placebo
15 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
16 Pirfenidone for Progressive Fibrotic Sarcoidosis Recruiting NCT03260556 Phase 4 Pirfenidone;Placebos
17 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
18 A Single Cohort Phase 4 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD Recruiting NCT03646123 Phase 4 brentuximab vedotin;doxorubicin;vinblastine;dacarbazine;G-CSF
19 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
20 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
21 Vitamin D Homeostasis in Sarcoidosis Not yet recruiting NCT03621553 Phase 4 Ergocalciferol;Placebo;Calcium Citrate with Vitamin D2
22 Use of CXCL9 as a Biomarker of Acthar Efficacy Not yet recruiting NCT02523092 Phase 4 Acthar gel
23 Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors Suspended NCT00701207 Phase 4 nicotine patch
24 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
25 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
26 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
27 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
28 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
29 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
30 ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial Unknown status NCT02348905 Phase 2, Phase 3 ACTHAR Gel 40 units twice weekly;ACTHAR Gel 80 units twice weekly.
31 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
32 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
33 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
34 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
35 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
36 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
37 Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
38 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
39 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
40 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
41 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
42 Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups Unknown status NCT00005584 Phase 3 ABVD regimen;BEACOPP regimen;epirubicin hydrochloride;prednisone;vinblastine sulfate
43 Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00851929 Phase 2, Phase 3 Ambrisentan
44 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Completed NCT01324999 Phase 2, Phase 3 Tadalafil
45 Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis Completed NCT00305552 Phase 3 THALIDOMIDE
46 The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis Completed NCT00794274 Phase 2, Phase 3 CC-100004
47 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
48 Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. Completed NCT01687517 Phase 3 Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
49 Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis Completed NCT00555347 Phase 2, Phase 3 Armodafinil;Placebo
50 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine
Chlorambucil
Chloroquine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Dexamethasone
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
Methylprednisolone
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: sarcoidosis

Genetic Tests for Sarcoidosis 1

Anatomical Context for Sarcoidosis 1

MalaCards organs/tissues related to Sarcoidosis 1:

41
Lung, T Cells, Lymph Node, Skin, Testes, Heart, Bone

Publications for Sarcoidosis 1

Articles related to Sarcoidosis 1:

(show top 50) (show all 23026)
# Title Authors PMID Year
1
HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. 38 8 71
14508706 2003
2
Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. 9 38 8
15702130 2005
3
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. 9 38 71
15735647 2005
4
Association between IFNA genotype and the risk of sarcoidosis. 9 38 8
15004750 2004
5
Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. 38 8
17591867 2007
6
Demographic-related variations in posterior segment ocular sarcoidosis. 38 8
15019390 2004
7
Results from a genome-wide search for predisposing genes in sarcoidosis. 38 8
11549543 2001
8
Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. 38 8
10580780 1999
9
[Familial sarcoidosis. 4 cases from 2 families]. 38 8
3070740 1988
10
Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. 38 8
3827423 1987
11
Familial occurrence of sarcoidosis and Crohn's disease. 38 8
6134089 1983
12
Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. 38 8
1067023 1976
13
Familial sarcoidosis: a possible genetic influence. 38 8
1067024 1976
14
Sarcoidosis and Crohn disease in siblings. 38 8
5558992 1971
15
Familial sarcoidosis. Report of four siblings with acute sarcoidosis. 38 8
5558993 1971
16
SARCOIDOSIS. I. FAMILIAL OCCURRENCE. II. PSEUDOTUMOR CEREBRI AND UNUSUAL SKIN LESIONS. 38 8
14104643 1964
17
Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. 38 8
13874291 1961
18
The role of positron emission tomography in the assessment of cardiac sarcoidosis. 38 17
31166768 2019
19
Sarcoidosis. 38 17
30955519 2019
20
Autoimmune liver disease (primary biliary cholangitis/autoimmune hepatitis-overlap) associated with sarcoidosis (clinical cases and literature review). 38 17
31090378 2019
21
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature. 9 38
20162506 2010
22
The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. 9 38
20070603 2010
23
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 9 38
19467619 2010
24
Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. 9 38
19910611 2010
25
CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. 9 38
19679608 2010
26
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. 9 38
19147181 2010
27
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 9 38
20082271 2010
28
A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. 9 38
19854854 2010
29
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. 9 38
19808030 2010
30
Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. 9 38
20022779 2010
31
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis. 9 38
20151281 2010
32
Targeting the TNF-alpha pathway in sarcoidosis. 9 38
20001207 2010
33
Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. 9 38
19966199 2009
34
Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. 9 38
20011602 2009
35
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. 9 38
19755199 2009
36
[Radiographic healing of sarcoid bone erosion]. 9 38
19756665 2009
37
Antimycobacterial immune responses in patients with pulmonary sarcoidosis. 9 38
20298409 2009
38
CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. 9 38
19386686 2009
39
Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. 9 38
19225544 2009
40
Hypothesis: sarcoidosis is a STAT1-mediated disease. 9 38
19464956 2009
41
Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation. 9 38
19842835 2009
42
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. 9 38
19259660 2009
43
Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. 9 38
19359344 2009
44
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 9 38
19117745 2009
45
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). 9 38
19585358 2009
46
Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. 9 38
19281539 2009
47
Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. 9 38
19220835 2009
48
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. 9 38
19077082 2009
49
Atypical sarcoidosis: case reports and review of the literature. 9 38
19530510 2009
50
Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? 9 38
19208587 2009

Variations for Sarcoidosis 1

ClinVar genetic disease variations for Sarcoidosis 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 HLA-DRB1 HLA-DRB1, HLA-DRB1*1101 undetermined variant risk factor

Expression for Sarcoidosis 1

Search GEO for disease gene expression data for Sarcoidosis 1.

Pathways for Sarcoidosis 1

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNFRSF1B TNF NOD2 MIF LTA IL2RA
2
Show member pathways
13.9 TNFRSF1B TNF LTA IL2RA IL1B IL18
3
Show member pathways
13.75 TNFRSF1B TNF MIF LTA IL2RA IL1B
4
Show member pathways
13.62 TNFRSF1B TNF LTA IL2RA IL1B IL18
5
Show member pathways
13.49 TNFRSF1B TNF LTA IL2RA IL1B IL18
6
Show member pathways
13.37 TNFRSF1B TNF LTA IL2RA IL1B IL18
7
Show member pathways
13.19 TNF NOD2 IL1B IL18 IFNG CCL3
8
Show member pathways
13.18 TNFRSF1B TNF NOD2 LTA IL2RA IL1B
9
Show member pathways
13 TNFRSF1B TNF IL1B ICAM1 CCL3 CCL2
10
Show member pathways
12.9 TNFRSF1B TNF LTA IL2RA IL1B IL18
11
Show member pathways
12.73 TNFRSF1B TNF IL2RA IL18 IL12RB1 IFNG
12
Show member pathways
12.72 TNFRSF1B TNF LTA IL1B IFNG
13
Show member pathways
12.68 TNF IL1B IL18 IL12RB1 IFNG CCL2
14
Show member pathways
12.66 TNF NOD2 IL2RA IL1B IL18 IL12RB1
15 12.65 TNFRSF1B TNF IL2RA IL1B IFNG CCL2
16 12.43 TNF LTA IL2RA ICAM1 HLA-DRB1
17
Show member pathways
12.41 TNF IL1B IFNG ICAM1 CCL2
18
Show member pathways
12.36 TNF IL1B IFNG CCL2
19
Show member pathways
12.36 TNF LTA IL2RA IL1B IL18 IFNG
20
Show member pathways
12.33 TNF MIF IL1B IFNG
21 12.33 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
22
Show member pathways
12.29 TNF IL1B IFNG HLA-DRB1
23 12.2 TNF IL1B IFNG ICAM1 CCL2
24
Show member pathways
12.17 TNF LTA IL1B IL18 IL12RB1 IFNG
25
Show member pathways
12.15 TNFRSF1B IL2RA IL1B IL18 IFNG ICAM1
26 12.13 TNF MIF IL1B IFNG ICAM1 CCL2
27 12.09 TNFRSF1B TNF IL1B IL18 ICAM1 CCL2
28
Show member pathways
12.03 IL2RA IL1B IL18 IL12RB1 IFNG HLA-DRB1
29 12 TNFRSF1B TNF NOD2 LTA IL1B ICAM1
30 11.99 TNF IL1B ICAM1 CCL2
31 11.99 TNF LTA IL1B ICAM1
32 11.98 TNF IL2RA IL1B HLA-DRB1
33 11.92 TNF IL1B IFNG
34 11.89 IL1B IL18 IFNG CCL3
35 11.82 TNF IL1B IL18 IFNG CCL3 CCL2
36
Show member pathways
11.79 TNF IL2RA IFNG
37
Show member pathways
11.79 TNF MIF IL1B IFNG ICAM1
38 11.77 TNF IL1B IFNG
39 11.77 TNF IL1B CCL3 CCL2
40
Show member pathways
11.68 TNF IL2RA IFNG
41
Show member pathways
11.66 TNFRSF1B TNF LTA IFNG
42 11.65 TNF IL1B IL18 IFNG CCL2
43 11.64 TNF IL1B IL18
44 11.62 TNFRSF1B TNF LTA
45 11.57 TNF IL1B IFNG
46 11.54 TNF IL1B IFNG
47 11.54 TNF IL1B IL18 IFNG ICAM1 CCL2
48 11.53 TNF IL1B IL18 IFNG ICAM1 HLA-DRB1
49 11.49 NOD2 IL1B IL18
50 11.48 TNF IL1B IL18 IFNG ICAM1

GO Terms for Sarcoidosis 1

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNFRSF1B TNF SCGB1A1 MIF LTA IL1B
2 cell surface GO:0009986 9.8 TNF NOD2 MIF IL2RA ICAM1 HLA-DRB1
3 extracellular space GO:0005615 9.73 TNF SCGB1A1 MIF LTA IL1B IL18
4 external side of plasma membrane GO:0009897 9.23 TNF IL2RA IL12RB1 ICAM1 HLA-DRB1 CXCR3

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 TNF MIF IL1B IFNG
2 MAPK cascade GO:0000165 9.99 TNF IL2RA IL1B IL18 CCL3 CCL2
3 response to lipopolysaccharide GO:0032496 9.98 TNFRSF1B SCGB1A1 LTA IL1B ICAM1
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TNF NOD2 IL1B IL18 ICAM1
5 cellular response to lipopolysaccharide GO:0071222 9.95 TNFRSF1B TNF NOD2 IL1B ICAM1 CCL2
6 inflammatory response GO:0006954 9.92 TNFRSF1B TNF MIF IL1B IL18 CXCR3
7 cell chemotaxis GO:0060326 9.91 CXCR3 CCL3 CCL2
8 positive regulation of JNK cascade GO:0046330 9.91 TNF NOD2 IL1B
9 neutrophil chemotaxis GO:0030593 9.91 IL1B CCL3 CCL2
10 cellular response to interleukin-1 GO:0071347 9.9 ICAM1 CCL3 CCL2
11 positive regulation of inflammatory response GO:0050729 9.9 TNF IL18 CCL3
12 chemokine-mediated signaling pathway GO:0070098 9.9 CXCR3 CCL3 CCL2
13 cellular response to interferon-gamma GO:0071346 9.9 IL12RB1 ICAM1 CCL3 CCL2
14 tumor necrosis factor-mediated signaling pathway GO:0033209 9.89 TNFRSF1B TNF LTA
15 regulation of inflammatory response GO:0050727 9.89 TNF SCGB1A1 NOD2
16 interferon-gamma-mediated signaling pathway GO:0060333 9.89 IFNG ICAM1 HLA-DRB1
17 regulation of insulin secretion GO:0050796 9.88 TNF IL1B IFNG
18 positive regulation of MAP kinase activity GO:0043406 9.88 TNF NOD2 MIF
19 humoral immune response GO:0006959 9.88 TNF LTA IFNG CCL2
20 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 TNF NOD2 MIF ICAM1 CCL3 CCL2
21 positive regulation of T cell proliferation GO:0042102 9.87 IL2RA IL1B BTNL2
22 positive regulation of interleukin-6 production GO:0032755 9.86 TNF NOD2 IL1B
23 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF NOD2 IL1B IL18
24 positive regulation of tumor necrosis factor production GO:0032760 9.85 NOD2 MIF CCL3
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 TNF IL1B IFNG ICAM1
26 interleukin-12-mediated signaling pathway GO:0035722 9.83 MIF IL12RB1 IFNG
27 protein kinase B signaling GO:0043491 9.83 TNF IL1B CCL3 CCL2
28 extrinsic apoptotic signaling pathway GO:0097191 9.82 TNFRSF1B TNF IFNG
29 negative regulation of T cell proliferation GO:0042130 9.81 SCGB1A1 IL2RA HLA-DRB1
30 positive regulation of interleukin-8 production GO:0032757 9.8 TNF NOD2 IL1B
31 positive regulation of activated T cell proliferation GO:0042104 9.79 IL2RA IL18 IL12RB1
32 positive regulation of glial cell proliferation GO:0060252 9.77 TNF LTA IL1B
33 positive regulation of interferon-gamma production GO:0032729 9.77 TNF LTA IL1B IL18 IL12RB1
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.74 NOD2 CCL2
35 positive regulation of interleukin-17 production GO:0032740 9.74 NOD2 IL18
36 macrophage chemotaxis GO:0048246 9.74 CCL3 CCL2
37 inflammatory response to antigenic stimulus GO:0002437 9.74 IL2RA HLA-DRB1
38 T cell chemotaxis GO:0010818 9.73 CXCR3 CCL3
39 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B IL18
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNFRSF1B TNF IL1B IFNG
41 T-helper 1 type immune response GO:0042088 9.72 IL18 HLA-DRB1
42 detection of bacterium GO:0016045 9.72 NOD2 HLA-DRB1
43 response to glucocorticoid GO:0051384 9.71 TNF SCGB1A1
44 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF IL1B
45 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
46 interleukin-6 production GO:0032635 9.69 IL1B IL18
47 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.68 TNF ICAM1
48 astrocyte cell migration GO:0043615 9.68 CCL3 CCL2
49 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.67 IL1B IL18
50 positive regulation of neuroinflammatory response GO:0150078 9.67 TNF IL1B IL18

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF MIF LTA IL1B IL18 IFNG

Sources for Sarcoidosis 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....